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Single-nucleotide polymorphisms (SNPs) in the 30 region of myosin IXB (MYO9B) gene have recently
been reported to associate with different inflammatory or autoimmune diseases. We monitored for the
association of MYO9B variants to multiple sclerosis (MS) in four Northern European populations. First,
18 SNPs including 6 SNPs with previous evidence for association to immune disorders, were tested in 730
Finnish MS families, but no linkage or family-based association was observed. To ensure the power to
detect variants with a modest effect size, we further analyzed 10 variants in 899 Finnish cases and 1325
controls, and in a total of 1521 cases and 1476 controls from Denmark, Norway and Sweden, but found no
association. Our results thereby do not support a major function of the tested MYO9B variants in MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of
the central nervous system, which leads to demyelination
and neurodegeneration. Although the exact etiology of MS
is unknown, it is considered a putative autoimmune
disease (AID) caused by a combination of multiple genetic
and environmental factors.1 Like many AIDs, MS has
consistently shown strong linkage and association to the
human leukocyte antigen (HLA) locus.
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In addition to the HLA, also other loci such as PTPN22
and CTLA4, have shown linkage or association with more
than one AID, indicating that AIDs may share some
common genetic background.2 More recently, allelic
variants in the gene encoding for myosin IXB (MYO9B)
have been reported to associate to different AIDs or
inflammatory disorders (ulcerative colitis, rheumatoid
arthritis, systemic lupus erythematosus and type 1 dia-
betes) following the initial report by Monsuur et al3 in
which association to celiac disease (CD) was found with six
MYO9B 30 region single-nucleotide polymorphisms (SNPs)
in the Dutch population.3 – 8 To further investigate the
relevance of MYO9B in different immune disorders, we
have tested the association of its genetic variants to MS in
four Northern European populations.
Materials and methods
Subjects and genotyping
The Finnish MS family sample consisted of 730 families
(340 full trios). Nineteen families were informative for
linkage containing 2–4 affected individuals and available
healthy family members. In the other families, one affected
and at least one healthy parent or sibling were genotyped.
The family cases were also included in a case–control
analysis with 169 additional Finnish MS patients, 1325
unrelated Finnish population controls and 1521 MS cases
and 1476 population controls from Denmark, Norway and
Sweden. All cases had been diagnosed according to Poser’s
criteria and informed consent was obtained from all
subjects. The study was approved by the ethics committees
of all institutions involved.
Figure 1 Haploblock structure of MYO9B based on HapMap CEPH genotype data. The coloring reflects level of linkage disequilibrium between
single-nucleotide polymorphisms (SNPs) in HapMap CEPH data, darker shades representing higher pairwise r2. The 10 SNPs genotyped in all samples
are indicated with black arrows. SNPs genotyped in Finnish MS families only are indicated with gray arrows. SNPs previously showing association to
other disorders are marked with asterisks.
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Eighteen tagging SNPs selected to represent all major
haploblocks in MYO9B were genotyped in 730 Finnish MS
families in two multiplexes (Figure 1). All genotyping was
conducted with Sequenom iPLEX platform (Sequenom
Inc., San Diego, CA, USA, detailed protocols and primer
sequences available on request). One of the multiplex
assays (10 SNPs) was then genotyped in cases and controls.
These 18 and 10 SNPs, respectively, capture 56 and 48% of
the variation in MYO9B in HapMap CEPH samples with
pairwise r 2¼0.7 (phase II data).9 Overall genotyping
success rate per SNP was 97–100% in all populations.
Statistical analysis
Power calculations were performed with the Genetic Power
Calculator.10 Haploview and PedCheck were used for
data quality checks (Hardy–Weinberg equilibrium P-value
Z0.01 in healthy family founders, cases and controls in all
populations, at most one Mendelian error/SNP).11,12
Family-based analyses were performed with Merlin
(nonparametric linkage test using Kong and Cox LOD
score),13 transmission disequilibrium test (TDT; Haploview)
and Gamete competition test (in Mendel software package
version 7.0), which uses families with missing genotype
data in addition to full trios.14,15 Case–control association
test was conducted as a two-tailed w2-test in Haploview.
Results and discussion
We first genotyped 18 SNPs including 6 SNPs with previous
association to other AIDs in 730 Finnish MS families. The
power to detect association at rs2305764 (P¼0.05) in TDT








rs3745349 C:T 0.55 0.60
rs7246865 G:A 0.61 0.89
rs8099879 C:A 0.63 0.19
rs7254359 A:G 0.91 0.60
rs10423232 T:C 0.70 0.11
rs17533868 C:T 0.73 0.22
rs17533945 T:C 0.74 0.84
rs11673417 C:G 0.41 0.44
rs12986130 C:A 0.26 0.18
rs2279006 C:T 0.58 0.03
rs3826689 G:T 0.11 0.29
rs962917 G:A 0.13 0.48
rs1545620 T:G 0.16 0.40
rs1457092 C:A 0.22 0.66
rs2279003 C:T 0.51 0.65
rs8107108 C:T 0.47 0.52
rs2305765 C:T 0.12 0.54
rs2305764 G:A 0.30 0.71
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was 0.96 assuming risk allele frequency of 35.7% and
odds ratios 1.66 and 2.27 for heterozygotes and homo-
zygotes, respectively, as reported by Monsuur et al3 for CD.
We did not observe significant evidence of association in
single SNP TDT or gamete competition tests (Table 1), or in
haplotype TDT. Furthermore, no evidence of linkage was
observed (Merlin nonparametric single point LOD scores
0.59–0.72).
We acknowledge, however, that with lower effect sizes
our family sample may have been underpowered to detect
association. We therefore genotyped a set of Northern
European MS cases and controls for a single multiplex of 10
SNPs. This included rs1457092, which efficiently tags the
CD risk haplotype identified by Monsuur et al,3 and has
been among the most strongly and consistently associated
SNPs in other studies. Concordantly with our results from
the family-based analysis, we failed to see evidence for
association in any single population or in combined
analysis (Cochran–Mantel–Haenszel test; Table 2).
Furthermore, no association was observed after stratifying
the cases for gender or HLA-DRB1*15 (results not shown).
Although association of MYO9B has been reported to
more than one AID or inflammatory disease, its role
remains controversial because of failed replication
efforts.16 – 21 In this study we tested the association of
MYO9B variants to yet another inflammatory disorder, MS,
but failed to find association. This is concordant with the
lack of association with MYO9B in the recent international
genomewide association study for MS,22 which, however,
contained no SNPs in the previously associated 30 haplo-
block. Considering the reasonable power of our sample, the
previously AID-associated MYO9B variants are unlikely to
be involved in MS.
Acknowledgements
We are indebted to the patients and their families for participation to
the study. This work was financially supported by Neuropromise EU
grant LSHM-CT-2005-018637, NIH grant NS 43559, The Center of
Excellence for Disease Genetics of the Academy of Finland, the Sigrid
Juselius Foundation, Helsinki University Central Hospital Research
Foundation and the Helsinki Biomedical Graduate School (AK). Large
scale DNA extraction and storage facility of the National Public
Health Institute is acknowledged for handling of Finnish samples. The
Norwegian Bone Marrow Donor Registry is acknowledged for
collaboration in establishment of the Norwegian control material.
References
1 Ebers GC: Environmental factors and multiple sclerosis. Lancet
Neurol 2008; 7: 268–277.
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